Argent BioPharma (ASX:RGT) and AusCann Group Holdings signed a strategic heads of agreement to advance cannabinoid-based pharmaceutical development through the exchange of proprietary datasets and regulatory expertise, according to a Tuesday Australian bourse filing.
AusCann will license Argent BioPharma's CannEpil CMC and Dossier specifically for non-epilepsy-related pharmaceutical programs.
The companies will also gain access to AusCann's proprietary self-emulsifying hard-shell capsule formulation, Neuvis, including access to pharmacokinetic and pharmacodynamic data.
The firms will also establish a joint steering committee to coordinate research and development efforts as well as optimize regulatory strategies.
The agreement also includes a deferred licensing fee structure, with royalties on pharmaceutical products developed using jointly leveraged data, research and development, or assets.
Financial terms were not disclosed.
Argent BioPharma's shares were down almost 3% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.